# Viyash Scientific (NSE: VIYASH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/VIYASH · Pivot · prices to 22 Oct 2026

Viyash Scientific (NSE: VIYASH) closed at ₹214.90 on 22 Oct 2026, down 0.05% on the day. With a market capitalisation of ₹9,388 Cr, it ranks 572nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 53.6× trailing earnings, against a return on equity of 3.1% in FY25. Over the past year the share price has risen 3.1%. Its 52-week range is ₹178.13 (23 Mar 2026) to ₹298.00 (6 Jul 2026); the last close is 27.9% below the high. Promoters held 61.31% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹214.90 |
| Market cap | ₹9,388 Cr |
| P/E (trailing) | 53.6 |
| ROE | 3.1% (FY25) |
| ROCE | 10.0% (FY25) |
| Debt to equity | 0.63 |
| 52-week high | ₹298.00 (6 Jul 2026) |
| 52-week low | ₹178.13 (23 Mar 2026) |
| 1-year return | +3.1% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,551 Cr | ₹32 Cr |
| FY24 | ₹1,370 Cr | −₹30 Cr |
| FY23 | ₹1,421 Cr | −₹122 Cr |
| FY22 | ₹1,413 Cr | ₹45 Cr |
| FY21 | ₹1,362 Cr | ₹104 Cr |
| FY20 | ₹1,179 Cr | ₹82 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 61.31%
- Foreign institutions: 4.50%
- Domestic institutions: 3.75%
- Non-institutions: 30.34%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Akums Drugs and Pharmaceuticals](https://app.pivotnow.in/stock/AKUMS) | ₹690.85 | ₹10,874 Cr | 41.5 | — |
| [Park Medi World](https://app.pivotnow.in/stock/PARKHOSPS) | ₹220.45 | ₹9,522 Cr | 32.1 | — |
| [Blue Jet Healthcare](https://app.pivotnow.in/stock/BLUEJET) | ₹499.60 | ₹9,456 Cr | 35 | — |
| [Strides Pharma Science](https://app.pivotnow.in/stock/STAR) | ₹1,017.30 | ₹9,377 Cr | 16.9 | — |
| [Yatharth Hospital & Trauma Care Services](https://app.pivotnow.in/stock/YATHARTH) | ₹932.10 | ₹8,981 Cr | 51.2 | — |
| [Healthcare Global Enterprises](https://app.pivotnow.in/stock/HCG) | ₹552.00 | ₹8,241 Cr | — | — |

## Questions and answers

### What is the share price of Viyash Scientific today?

Viyash Scientific (NSE: VIYASH) last closed at ₹214.90 on 22 Oct 2026. Its 52-week high is ₹298.00 and its 52-week low is ₹178.13.

### What is the market cap of Viyash Scientific?

Viyash Scientific's market capitalisation is ₹9,388 Cr (₹9,388 Cr) at the 22 Oct 2026 close, ranking 572nd among the NSE companies Pivot tracks.

### What is the P/E ratio of Viyash Scientific?

Viyash Scientific trades at a trailing P/E of 53.6. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 35.

### What is the ROE and ROCE of Viyash Scientific?

Return on equity was 3.1% in FY25 and return on capital employed was 10.0% in FY25 (consolidated figures).

### Is Viyash Scientific a debt-free company?

No. Viyash Scientific's debt-to-equity ratio was 0.63 in FY25, with total debt of ₹274 Cr.

### How has Viyash Scientific stock performed over the last year?

Viyash Scientific's share price has risen 3.1% over the past year, −16.2% over three months and −14.3% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Viyash Scientific?

As of 30 Jun 2026: promoters 61.31%, foreign institutions 4.50%, domestic institutions 3.75%, non-institutions 30.34%.

### Who are Viyash Scientific's competitors?

The listed Pharma & Healthcare companies closest to Viyash Scientific by market cap are Akums Drugs and Pharmaceuticals, Park Medi World, Blue Jet Healthcare, Strides Pharma Science, Yatharth Hospital & Trauma Care Services and Healthcare Global Enterprises.

### Is Viyash Scientific a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Viyash Scientific's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VIYASH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.